Skip to main
LFCR
LFCR logo

LFCR Stock Forecast & Price Target

LFCR Analyst Ratings

Based on 1 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Lifecore Biomedical is projected to experience substantial growth with EBITDA increasing from $24.6 million in FY26 at a margin of 16.8% to $27.3 million in FY27 at a margin of 19.1%. Additionally, the company's free cash flow is expected to rise from $5.1 million in FY26 to $6.0 million in FY27, reflecting improved financial health. These metrics indicate a positive trajectory for operational efficiency and profitability within the contract development and manufacturing space.

Bears say

Lifecore Biomedical's stock outlook is negatively impacted by a projected revenue growth rate that is expected to lag behind market averages, particularly in the fill/finish segment influenced by small molecule injectables. The company's high leverage ratio further complicates its financial position, suggesting increased risk when compared to peers. Additionally, the anticipated lack of meaningful revenue growth until calendar year 2027 raises concerns about the company's ability to generate profits in the near term.

LFCR has been analyzed by 1 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lifecore Biomedical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lifecore Biomedical Inc (LFCR) Forecast

Analysts have given LFCR a Hold based on their latest research and market trends.

According to 1 analysts, LFCR has a Hold consensus rating as of Nov 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lifecore Biomedical Inc (LFCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.